Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 25Lymphoma 21Neutropenia 13Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 11Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Carcinoma, Non-Small-Cell Lung 8Multiple Myeloma 7Leukemia 7Burkitt Lymphoma 7Ovarian Neoplasms 6Lymphoma, Follicular 6Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Urinary Bladder Neoplasms 4Testicular Neoplasms 4Sarcoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Hodgkin Disease 4Central Nervous System Neoplasms 4Testicular Germ Cell Tumor 3Teratoma 3Rhabdomyosarcoma 3Chemotherapy-induced Neutropenia 3Carcinoma, Ovarian Epithelial 3Carcinoma, Embryonal 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1pazopanib 1ixabepilone 1Thalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recurrent Uterine Corpus Sarcoma × pegfilgrastim × Clear all
NCT00031629 2016-12-08

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

GOG Foundation

Phase 2 Completed
51 enrolled
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡